GatePass Capital LLC Lowers Stock Holdings in Pfizer Inc. $PFE

GatePass Capital LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 52.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,129 shares of the biopharmaceutical company’s stock after selling 25,887 shares during the period. GatePass Capital LLC’s holdings in Pfizer were worth $576,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the period. State Street Corp lifted its stake in shares of Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after acquiring an additional 2,786,098 shares during the period. Northern Trust Corp boosted its holdings in shares of Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after acquiring an additional 869,175 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Pfizer by 5.4% in the fourth quarter. Fisher Asset Management LLC now owns 51,952,106 shares of the biopharmaceutical company’s stock valued at $1,293,607,000 after acquiring an additional 2,664,052 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Pfizer by 2.7% during the fourth quarter. Legal & General Group Plc now owns 42,864,225 shares of the biopharmaceutical company’s stock worth $1,067,319,000 after acquiring an additional 1,123,039 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. UBS Group increased their target price on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Monday, April 13th. Royal Bank Of Canada reissued an “underperform” rating and issued a $25.00 price target on shares of Pfizer in a report on Monday, April 20th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Morgan Stanley increased their price objective on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.61.

Pfizer Stock Performance

NYSE PFE opened at $25.92 on Tuesday. The business has a 50 day moving average price of $26.84 and a 200 day moving average price of $26.25. The company has a market capitalization of $147.72 billion, a P/E ratio of 19.79 and a beta of 0.35. Pfizer Inc. has a 1-year low of $22.88 and a 1-year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the prior year, the company earned $0.92 earnings per share. Pfizer’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.